Foundation Fighting Blindness will provide up to $7.5 million in funding to develop ProQR’s candidate QR-421a for Usher syndrome type 2A
February 12, 2018 07:00 ET
|
ProQR Therapeutics N.V.; Foundation Fighting Blindness
Foundation Fighting Blindness and ProQR enter into a partnership to develop QR-421a for Usher syndrome type 2A, targeting mutations in exon 13 of the causative USH2A gene. Foundation Fighting...
ProQR to Present at Upcoming Scientific Meeting and Investor Conference
February 06, 2018 07:00 ET
|
ProQR Therapeutics N.V.
LEIDEN, the Netherlands, Feb. 06, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the...
ProQR and Galapagos Announce Research Collaboration on Fibrosis Targets Using ProQR’s Axiomer® technology
January 08, 2018 07:00 ET
|
ProQR Therapeutics N.V.
LEIDEN, the Netherlands, Jan. 08, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR), today announced that it has entered into a research collaboration agreement with Galapagos N.V....
ProQR Announces Extraordinary General Meeting of Shareholders
December 27, 2017 07:00 ET
|
ProQR Therapeutics N.V.
LEIDEN, the Netherlands, Dec. 27, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.(Nasdaq:PRQR), today announced that an Extraordinary General Meeting of Shareholders will be held on Monday,...
ProQR Receives Orphan Drug Designation from EMA for Drug Candidate QR-313 for Dystrophic Epidermolysis Bullosa
November 29, 2017 07:00 ET
|
ProQR Therapeutics N.V.
Key Updates ProQR’s drug candidate, QR-313 for dystrophic epidermolysis bullosa (DEB) receives orphan drug designation in the EU from the EMA.QR-313 also received U.S. ODD from the FDA in September...
ProQR to Present at the Annual Piper Jaffray Healthcare Conference
November 21, 2017 07:00 ET
|
ProQR Therapeutics N.V.
LEIDEN, the Netherlands, Nov. 21, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.(Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the...
ProQR Announces Results for the Third Quarter of 2017
November 20, 2017 07:00 ET
|
ProQR Therapeutics N.V.
Key updates Runway into the second half of 2019: cash of €39.7 million at end of Q3, increased by gross proceeds of approximately $20 million from an issuance of ordinary shares in November 2017 that...
ProQR Doses First LCA 10 Patient in Clinical Trial of QR-110, ProQR’s Lead Program for Genetic Blindness
November 13, 2017 07:00 ET
|
ProQR Therapeutics N.V.
Key Updates The first patient has received the first dose of QR-110 in the Phase 1/2 safety & efficacy clinical trial (PQ-110-001: NCT03140969) in children and adults with Leber’s congenital...
ProQR Appoints Thaddeus Dryja, M.D. to Scientific Advisory Board
November 09, 2017 07:00 ET
|
ProQR Therapeutics N.V.
Key Updates Dr. Thaddeus (Ted) Dryja, a pioneer in the field of retinal genetic diseases, joins the Company’s Scientific Advisory Board.Dr. Dryja will play a key strategic role in the development and...
ProQR to Present at EuroTIDES Conference
October 31, 2017 07:00 ET
|
ProQR Therapeutics N.V.
LEIDEN, The Netherlands, Oct. 31, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the...